Paragon Capital Management LTD Lifted Its Microsoft (MSFT) Holding; As Horizon Pharma Plc (HZNP) Shares Rose, Zacks Investment Management Has Cut Its Holding

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Logo

Paragon Capital Management Ltd increased its stake in Microsoft Corp (MSFT) by 70.44% based on its latest 2019Q1 regulatory filing with the SEC. Paragon Capital Management Ltd bought 32,299 shares as the company’s stock rose 17.99% with the market. The institutional investor held 78,149 shares of the prepackaged software company at the end of 2019Q1, valued at $9.22M, up from 45,850 at the end of the previous reported quarter. Paragon Capital Management Ltd who had been investing in Microsoft Corp for a number of months, seems to be bullish on the $ market cap company. The stock increased 0.25% or $0.35 during the last trading session, reaching $138.75. About 8.70 million shares traded. Microsoft Corporation (NASDAQ:MSFT) has risen 28.55% since July 12, 2018 and is uptrending. It has outperformed by 24.12% the S&P500. Some Historical MSFT News: 26/04/2018 – MICROSOFT CFO SAYS DYNAMICS 365 AND LINKEDIN SHOULD ALSO CONTINUE TO DRIVE DOUBLE-DIGIT REVENUE GROWTH – CONF CALL; 20/04/2018 – Amazon, Microsoft, Intel, and Google are among 10 U.S. tech companies snapping up foreign-worker visas; 17/05/2018 – Vology Welcomes Mike Ehresman as Vice President of Sales Enablement; 27/04/2018 – DIGIMARC CORP – ANNOUNCED A NEW 15-YEAR PARTNERSHIP WITH MICROSOFT; 16/05/2018 – Techmeme: Sources: Microsoft is planning a line of lower-cost 10-inch Surface tablets priced at about $400 with USB-C; 07/03/2018 – BluChip Solutions, an ITPS Company, Partners with 2 of the Largest Universities in the Country to Launch Microsoft Office 365 P; 08/03/2018 – Microsoft Corporation vs Improved Search LLC | Terminated-Adverse Judgment | 03/08/2018; 21/05/2018 – Cerner Announces Amendment to Share Repurchase Program; 14/03/2018 – Socionext to Showcase the World’s Smallest 8K Media Player at Digital Signage Expo; 01/05/2018 – Paramount Defenses Releases Gold Finger Mini 6.0 for Microsoft Active Directory to Democratize Cyber Intelligence Worldwide

Zacks Investment Management decreased its stake in Horizon Pharma Plc (HZNP) by 20% based on its latest 2019Q1 regulatory filing with the SEC. Zacks Investment Management sold 14,176 shares as the company’s stock rose 15.66% with the market. The institutional investor held 56,696 shares of the major pharmaceuticals company at the end of 2019Q1, valued at $1.50M, down from 70,872 at the end of the previous reported quarter. Zacks Investment Management who had been investing in Horizon Pharma Plc for a number of months, seems to be less bullish one the $4.31 billion market cap company. The stock decreased 1.06% or $0.25 during the last trading session, reaching $23.33. About 439,919 shares traded. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) has risen 77.97% since July 12, 2018 and is uptrending. It has outperformed by 73.54% the S&P500. Some Historical HZNP News: 09/05/2018 – HORIZON PHARMA BOOSTS YEAR 2018 GUIDANCE; 03/05/2018 – AGC BIOLOGICS, HORIZON PHARMA IN COMMERCIAL MANUFACTURING PACT; 09/05/2018 – Horizon Pharma 1Q Loss $157.3M; 14/05/2018 – Horizon Pharma Closes Above 50-Day Moving Average: Technicals; 09/05/2018 – Horizon Pharma plc Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth; Increases Full-Year 2018 Guidanc; 03/05/2018 – AGC Biologics Enters into Commercial Manufacturing Agreement with Horizon Pharma plc; 09/05/2018 – HORIZON PHARMA PLC REPORTS STRONG FIRST-QUARTER 2018 ORPHAN AND RHEUMATOLOGY NET SALES GROWTH; INCREASES FULL-YEAR 2018 GUIDANCE AND ANNOUNCES NEW COMPANY OPERATING STRUCTURE TO ENHANCE; 08/05/2018 – HORIZON PHARMA GETS 2 NOTICES OF ALLOWANCE ON RAVICTI PATENTS; 09/05/2018 – Horizon Pharma 1Q EBITDA $33.6M; 08/05/2018 – HORIZON PHARMA: PATENTS SCHEDULED TO EXPIRE ON SEPT. 22, 2030

Since February 5, 2019, it had 0 buys, and 1 insider sale for $204,559 activity.

Analysts await Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) to report earnings on August, 14. They expect $0.39 earnings per share, down 18.75% or $0.09 from last year’s $0.48 per share. HZNP’s profit will be $72.10M for 14.96 P/E if the $0.39 EPS becomes a reality. After $0.30 actual earnings per share reported by Horizon Therapeutics Public Limited Company for the previous quarter, Wall Street now forecasts 30.00% EPS growth.

Investors sentiment increased to 1.99 in 2019 Q1. Its up 0.66, from 1.33 in 2018Q4. It is positive, as 20 investors sold HZNP shares while 58 reduced holdings. 71 funds opened positions while 84 raised stakes. 151.47 million shares or 10.95% more from 136.51 million shares in 2018Q4 were reported. Gideon Cap holds 0.31% or 32,513 shares in its portfolio. Sg Americas Securities Ltd Com reported 19,606 shares or 0% of all its holdings. Granite Investment Prtnrs Limited Com invested 0.09% of its portfolio in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). 735,594 were accumulated by Parametric Portfolio Associates Ltd Liability Company. Jennison Ltd Liability Corp reported 2.20M shares stake. Illinois-based Alyeska Inv Grp Ltd Partnership has invested 0.27% in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). Us Bancshares De, Minnesota-based fund reported 64,175 shares. At Commercial Bank holds 25,277 shares or 0.08% of its portfolio. C Worldwide Gp Hldg A S stated it has 0.06% in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). Emerald Mutual Fund Advisers Trust has 1.26% invested in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). Oakworth Capital has 318 shares for 0% of their portfolio. Nuveen Asset Ltd Liability has 0.01% invested in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) for 83,225 shares. Aqr Cap Ltd Company holds 0.01% or 284,521 shares in its portfolio. Capital Fund Mgmt stated it has 0.06% in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). Engineers Gate Manager Ltd Partnership has invested 0.02% in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP).

More notable recent Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) news were published by: Finance.Yahoo.com which released: “Here’s What Hedge Funds Think About SYNNEX Corporation (SNX) – Yahoo Finance” on June 28, 2019, also Streetinsider.com with their article: “Horizon Pharma (HZNP) Receives CID from US Department of Justice Pursuant to Federal False Claims Act – StreetInsider.com” published on March 05, 2019, Businesswire.com published: “Horizon Therapeutics plc Announces Pricing of Private Offering of Senior Notes – Business Wire” on July 11, 2019. More interesting news about Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) were released by: Seekingalpha.com and their article: “Horizon Pharma completes enrollment in late-stage study of teprotumumab in thyroid eye disease – Seeking Alpha” published on September 04, 2018 as well as Seekingalpha.com‘s news article titled: “Goldman confident with sales forecast for Horizon Pharma’s gout drug Krystexxa despite potential threat from Selecta Bio’s SEL-212 – Seeking Alpha” with publication date: August 23, 2018.

Zacks Investment Management, which manages about $3.45 billion and $4.66 billion US Long portfolio, upped its stake in M & T Bk Corp (NYSE:MTB) by 28,505 shares to 58,252 shares, valued at $9.15 million in 2019Q1, according to the filing. It also increased its holding in Wells Fargo Co New (NYSE:WFC) by 294,725 shares in the quarter, for a total of 1.45 million shares, and has risen its stake in International Business Machs (NYSE:IBM).

Paragon Capital Management Ltd, which manages about $706.03 million and $165.23 million US Long portfolio, decreased its stake in Vanguard Scottsdale Fds (VCSH) by 3,895 shares to 14,646 shares, valued at $1.17M in 2019Q1, according to the filing.

Since February 6, 2019, it had 0 buys, and 1 sale for $28.35 million activity.

Microsoft Corporation (NASDAQ:MSFT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.